title: Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study.
abstract: A peritoneal dialysis (PD) solution containing 1.1% amino acids as the osmotic agent was evaluated in a 3-month randomized, prospective, open-label study in malnourished PD patients. Patients in the treatment group (DAA) received one or two exchanges daily with the amino acid solution, depending on tolerance, in place of glucose solutions. Controls (DD) received their usual therapy with glucose dialysate. Fifty-four DAA and 51 DD patients completed the study. In DAA, but not in DD patients, there was a significant increase at month 3 in serum insulin-like growth factor-1 (IGF-1) levels and significant decreases in serum potassium (all 3 months) and inorganic phosphorus levels (months 1 and 3), indicating a general anabolic response. Prealbumin and transferrin levels were significantly increased in DAA but not in DD patients at month 1, but the groups did not differ at months 2 and 3. In patients with baseline albumin levels less than 3.5 g/dL (bromcresol green [BCG] method), DAA patients showed increases in albumin, transferrin (months 1 and 2), and prealbumin levels (all 3 months) relative to baseline values, whereas these serum protein levels were unchanged in DD patients, although the changes from baseline did not differ between groups. In this subgroup, midarm muscle circumference (MAMC) did not change in DD or DAA patients. In patients with baseline albumin levels of 3.5 g/dL or greater, DD patients had decreases in albumin and total protein levels at all 3 months and in prealbumin levels at months 1 and 2, relative to baseline. In DAA patients, there were fewer changes in serum proteins. MAMC increased significantly from baseline in DAA but not in DD patients, although changes from baseline did not differ between DAA and DD groups. DAA patients showed no changes in peritoneal membrane transport characteristics. The results indicate that treatment with one or two exchanges daily of this amino acid-based PD solution is safe and provides nutritional benefit for malnourished PD patients.
authors.affiliation: Baxter Healthcare Renal Division, McGaw Park, IL 60085, USA. jonesmi@baxter.com
authors.forename: M
authors.initials: M
authors.lastname: Jones
authors.forename: T
authors.initials: T
authors.lastname: Hagen
authors.forename: C A
authors.initials: CA
authors.lastname: Boyle
authors.forename: E
authors.initials: E
authors.lastname: Vonesh
authors.forename: R
authors.initials: R
authors.lastname: Hamburger
authors.forename: C
authors.initials: C
authors.lastname: Charytan
authors.forename: S
authors.initials: S
authors.lastname: Sandroni
authors.forename: D
authors.initials: D
authors.lastname: Bernard
authors.forename: B
authors.initials: B
authors.lastname: Piraino
authors.forename: M
authors.initials: M
authors.lastname: Schreiber
authors.forename: T
authors.initials: T
authors.lastname: Gehr
authors.forename: P
authors.initials: P
authors.lastname: Fein
authors.forename: M
authors.initials: M
authors.lastname: Friedlander
authors.forename: J
authors.initials: J
authors.lastname: Burkart
authors.forename: D
authors.initials: D
authors.lastname: Ross
authors.forename: S
authors.initials: S
authors.lastname: Zimmerman
authors.forename: R
authors.initials: R
authors.lastname: Swartz
authors.forename: T
authors.initials: T
authors.lastname: Knight
authors.forename: A
authors.initials: A
authors.lastname: Kraus
authors.forename: L
authors.initials: L
authors.lastname: McDonald
authors.forename: M
authors.initials: M
authors.lastname: Hartnett
authors.forename: M
authors.initials: M
authors.lastname: Weaver
authors.forename: L
authors.initials: L
authors.lastname: Martis
authors.forename: J
authors.initials: J
authors.lastname: Moran
mesh_terms: D000596:Amino Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D001132:Arm / Q000033:anatomy & histology; D001798:Blood Proteins / Q000032:analysis; D015314:Dialysis Solutions / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D008875:Middle Aged; D018482:Muscle, Skeletal / Q000033:anatomy & histology; D009748:Nutrition Disorders / Q000628:therapy*; D009995:Osmosis; D010531:Peritoneal Dialysis, Continuous Ambulatory / Q000379:methods*; D010537:Peritoneum / Q000378:metabolism; D010710:Phosphates / Q000097:blood; D011188:Potassium / Q000097:blood; D011228:Prealbumin / Q000032:analysis; D011446:Prospective Studies; D012709:Serum Albumin / Q000032:analysis; D014168:Transferrin / Q000032:analysis
chemical_list: D000596:Amino Acids; D001798:Blood Proteins; D015314:Dialysis Solutions; D010710:Phosphates; D011228:Prealbumin; D012709:Serum Albumin; D014168:Transferrin; D007334:Insulin-Like Growth Factor I; D005947:Glucose; D011188:Potassium